Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25477376 | 0.96 | MEN1 (0.34) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL25507216 | 0.92 | MEN1 (0.36) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL24480320 | 0.83 | — | — | |
| SCHEMBL24827983 | 0.82 | MEN1 (0.32) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL25467824 | 0.81 | HTR6 (0.32) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL25659233 | 0.81 | — | — | |
| SCHEMBL24827973 | 0.79 | CYP2D6 (0.46) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL25518688 | 0.79 | CYP2D6 (0.46) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL107432 | 0.79 | OPRL1 (0.38) | MEN1KMT2ACYP2D6KCNH2HRH3 | |
| SCHEMBL24185791 | 0.79 | OPRL1 (0.38) | MEN1KMT2ACYP2D6KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180427-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |